Drug intelligence / Profile preview

S315

Development stage: Phase 1
Lead developer: MassBiologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

S315 is a human monoclonal antibody developed by MassBiologics for the treatment of diphtheria. It is designed to target and neutralize Diphtheria Toxin. Clinical trials are underway to evaluate its safety and pharmacokinetics in healthy subjects.

Targets

HBEGF (Heparin-binding EGF-like growth factor)

Beyond the preview

Go deeper on S315.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S315.

Explore the full profile